样式: 排序: IF: - GO 导出 标记为已读
-
Population pharmacokinetic/pharmacodynamic modeling of H018, a selective JAK1 inhibitor, in healthy Chinese volunteers Eur. J. Pharm. Sci. (IF 4.6) Pub Date : 2024-03-11 Yuchen Qu, Wenjia Zhou, Meng Wang, Quanying Zhang, Mei Su, Jie Pan
H018 is an orally administered, selective, small-molecule inhibitor of Janus kinase 1 (JAK1) made for the treatment of rheumatoid arthritis. A population pharmacokinetic/pharmacodynamic analysis was conducted to characterize the pharmacokinetic and pharmacodynamic profile of H018 and its active metabolite using data from 48 healthy Chinese volunteers who received a single dose of 10–160 mg of H018
-
Application of Bootstrap f2 to Dissolution Data From Biorelevant Media and Evidence of the Conservative Nature of Bootstrap f2 Eur. J. Pharm. Sci. (IF 4.6) Pub Date : 2024-03-11 Raqeeb Jamil, James E. Polli
with or without bootstrapping is the most common method to compare in vitro dissolution profiles, but methods to compare dissolution profiles have become less harmonized. The objective was to compare outcomes from bootstrap and (i.e. not-bootstrapped ) using a large set of in vitro dissolution data. Non-parametric bootstrapping was performed on the 104 profile comparisons that did not meet the percent
-
Distribution and suitability of pulmonary surfactants as a vehicle for topically applied antibodies in healthy and SARS-CoV-2 infected rodent lungs. Eur. J. Pharm. Sci. (IF 4.6) Pub Date : 2024-03-11 Lea-Adriana Barlang, Isabelle Deimel, Björn-Patrick Mohl, Claudia Blaurock, Anne Balkema-Buschmann, Kristina Weinbender, Brian Hess, Helena Obernolte, Olivia M. Merkel, Andreas Popp
The use of natural pulmonary surfactants (PS) as a drug delivery vehicle for biologics is a more recent therapeutic modality. Herein, we tested different contents of PS regarding their physicochemical properties under stress conditions. The PS content of 12.25 mg/ml (Formulation B) showed desired properties such as an isotonic osmolality ∼300 mOsm/kg and an acceptable viscosity of 8.61 cSt, being lower
-
In vitro and in ovo photodynamic efficacy of nebulized curcumin-loaded tetraether lipid liposomes prepared by DC as stable drug delivery system Eur. J. Pharm. Sci. (IF 4.6) Pub Date : 2024-03-11 Lena Bender, Eduard Preis, Konrad H. Engelhardt, Muhammad Umair Amin, Abdallah M. Ayoub, Damiano Librizzi, Valeri Roschenko, Jan Schulze, Behrooz H. Yousefi, Jens Schaefer, Udo Bakowsky
Lung cancer is one of the most common causes of high mortality worldwide. Current treatment strategies, e.g., surgery, radiotherapy, chemotherapy, and immunotherapy, insufficiently affect the overall outcome. In this study, we used curcumin as a natural photosensitizer in photodynamic therapy and encapsulated it in liposomes consisting of stabilizing tetraether lipids aiming for a pulmonary drug delivery
-
Environmental considerations along the life cycle of pharmaceuticals: Interview study on views regarding environmental challenges, concerns, strategies, and prospects within the pharmaceutical industry Eur. J. Pharm. Sci. (IF 4.6) Pub Date : 2024-03-07 Sanja Riikonen, Johanna Timonen, Tiina Sikanen
[Display omitted]
-
Regional lung targeting with a fluticasone/salmeterol aerosol using a bolus breath hold method of the PreciseInhale® system: A first evaluation in humans Eur. J. Pharm. Sci. (IF 4.6) Pub Date : 2024-03-07 Per Gerde, Carl-Olof Sjöberg, Helen Bäckroos, Joakim Englund, Marit Wangheim, Helena Litorp
In development of inhaled drugs- and formulations the measured concentration in the systemic circulation is often used as a surrogate for local dosimetry in the lungs. To further elucidate regional differences in the fate of drugs in the lungs, different aerodynamic sizes of aerosols have been used to target major airway regions. An alternative approach to achieve regional targeting of aerosols, is
-
Open forum conference on the ICH M13A bioequivalence guideline Eur. J. Pharm. Sci. (IF 4.6) Pub Date : 2024-03-05 Henning Blume, Steven Wedemeyer, Anne Seidlitz, Gerald Beuerle, Sandra Klein, Erem Bilensoy
The Network on Bioavailability and Biopharmaceutics of EUFEPS (European Federation for Pharmaceutical Sciences) had organised an Open Discussion Forum on the ICH M13A draft “Guideline on bioequivalence for immediate-release solid oral dosage forms”. This conference was cosponsored by the Arbeitsgemeinschaft Pharmazeutische Verfahrenstechnik (APV) and the Frankfurt Foundation Quality of Medicines. Scientists
-
The 2-aminoethyl diphenylborinate-based fluorescent method identifies quercetin and luteolin metabolites as substrates of Organic anion transporting polypeptides, OATP1B1 and OATP2B1 Eur. J. Pharm. Sci. (IF 4.6) Pub Date : 2024-03-02 Hana Kaci, Éva Bakos, Paul W. Needs, Paul A. Kroon, Kateřina Valentová, Miklós Poór, Csilla Özvegy-Laczka
Organic anion transporting polypeptides (OATPs), OATP1B1 and OATP2B1 are membrane proteins mediating the cellular uptake of chemically diverse organic compounds. OATP1B1 is exclusively expressed in hepatocytes and plays a key role in hepatic detoxification. The ubiquitously expressed OATP2B1 promotes the intestinal absorption of orally administered drugs. Flavonoids are widely found in foods and beverages
-
Virtual special issue of Nordic POP: Patient-oriented products Eur. J. Pharm. Sci. (IF 4.6) Pub Date : 2024-03-01 Jessica M. Rosenholm, Gøril Eide Flaten, Alexandra Teleki
-
Microfluidics produced ATRA-loaded PLGA NPs reduced tuberculosis burden in alveolar epithelial cells and enabled high delivered dose under simulated human breathing pattern in 3D printed head models Eur. J. Pharm. Sci. (IF 4.6) Pub Date : 2024-02-26 Ahmad Z. Bahlool, Brenton Cavanagh, Andrew O’ Sullivan, Ronan MacLoughlin, Joseph Keane, Mary P O’ Sullivan, Sally-Ann Cryan
Tuberculosis, caused by (Mtb), is second only to COVID-19 as the top infectious disease killer worldwide. Multi-drug resistant TB (MDR-TB) may arise because of poor patient adherence to medications due to lengthy treatment duration and side effects. Delivering novel host directed therapies (HDT), like all trans retinoic acid (ATRA) may help to improve drug regimens and reduce the incidence of MDR-TB
-
Miniaturized screening and performance prediction of tailored subcutaneous extended-release formulations for preclinical in vivo studies Eur. J. Pharm. Sci. (IF 4.6) Pub Date : 2024-02-24 Marco Block, Peter Sieger, Cornelius Truenkle, Christoph Saal, Roman Simon, Ines Truebenbach
-
Development and characterization of solid lipid-based formulations (sLBFs) of ritonavir utilizing a lipolysis and permeation assay Eur. J. Pharm. Sci. (IF 4.6) Pub Date : 2024-02-24 Arne Schulzen, Ioannis I. Andreadis, Christel A.S. Bergström, Julian Quodbach
As a high number of active pharmaceutical ingredients (APIs) under development belong to BCS classes II and IV, the need for improving bioavailability is critical. A powerful approach is the use of lipid-based formulations (LBFs) that usually consist of a combination of liquid lipids, cosolvents, and surfactants. In this study, ritonavir loaded solid LBFs (sLBFs) were prepared using solid lipid excipients
-
Intrinsic immunogenicity of liposomes for tuberculosis vaccines: Effect of cationic lipid and cholesterol Eur. J. Pharm. Sci. (IF 4.6) Pub Date : 2024-02-20 M.M. Szachniewicz, M.A. Neustrup, K.E. van Meijgaarden, W. Jiskoot, J.A. Bouwstra, M.C. Haks, A. Geluk, T.H.M. Ottenhoff
Tuberculosis (TB) is still among the deadliest infectious diseases, hence there is a pressing need for more effective TB vaccines. Cationic liposome subunit vaccines are excellent vaccine candidates offering effective protection with a better safety profile than live vaccines. In this study, we aim to explore intrinsic adjuvant properties of cationic liposomes to maximize immune activation while minimizing
-
Solubility of digitoxin in supercritical CO2: Experimental study and modeling Eur. J. Pharm. Sci. (IF 4.6) Pub Date : 2024-02-20 Mohammadreza Sheikhi-Kouhsar, Hamidreza Bagheri, Fahad Alsaikhan, Ahmed Khalid Aldhalmi, Hanan Hassan Ahmed
In this communication, the solubility of drug in supercritical CO was studied at different operating conditions (311 < (K) < 343, 120 < (bar) < 300). The results revealed drug solubility (in mole fraction) was between 0.095 × 10 to 1.12 × 10. In the case of thermodynamic solubility modeling, cubic and non-cubic equation of states i.e. SAFT (statistical associating fluid theory), SRK (Soave-Redlich-Kwong)
-
A study on the quantity, type, economic value and reasons for pharmaceutical waste returned to pharmacies in Finland Eur. J. Pharm. Sci. (IF 4.6) Pub Date : 2024-02-16 Mella Louhisalmi, Piia Lavikainen, Charlotta Sandler, Sonja Kallio, Risto Kanerva, Janne Martikainen, Johanna Timonen
Some medicines purchased are not used, resulting in pharmaceutical waste. Finland, among many other countries, is seeking to reduce the amount of pharmaceutical waste, but little information on this is currently available. This study aimed to evaluate the quantity, type, economic value, and reasons for returning pharmaceutical waste from households to community pharmacies in Finland. Community pharmacies
-
Implementing physics-based digital patient twins to tailor the switch of oral morphine to transdermal fentanyl patches based on patient physiology Eur. J. Pharm. Sci. (IF 4.6) Pub Date : 2024-02-13 Flora Bahrami, René Michel Rossi, Katelijne De Nys, Markus Joerger, Milena Cukic Radenkovic, Thijs Defraeye
Fentanyl transdermal patches are widely implemented for cancer-induced pain treatment due to the high potency of fentanyl and gradual drug release. However, transdermal fentanyl up-titration for opioid-naïve patients is difficult, which is why opioid treatment is often started with oral/iv morphine. Based on the daily dose of morphine, the initial dose of the fentanyl patch is decided upon. After reaching
-
Equivalence assessment of creams with quali-quantitative differences in light of the EMA and FDA regulatory framework Eur. J. Pharm. Sci. (IF 4.6) Pub Date : 2024-02-12 Paola Volontè, Umberto M. Musazzi, Luca Arnaboldi, Marco A. Ortenzi, Antonella Casiraghi, Francesco Cilurzo, Paola Minghetti
EMA and FDA are upgrading guidelines on assessing the quality and the equivalence of topically applied drug products for developing copies of originator products and supporting post-marketing variations. For topical products having remarkably similar composition, both EMA and FDA accept the equivalence on the bases of the comparison of rheological properties and in vitro drug release constant () and
-
iRGD mediated pH-responsive mesoporous silica enhances drug accumulation in tumors Eur. J. Pharm. Sci. (IF 4.6) Pub Date : 2024-02-10 Xiaoning Wang, Guangyang Zhao, Mengru Yan, Xiaoyan Liang, Ning Zhao, Tingli Lu
The limited penetration of nanocarriers into tumors and the slow release of drugs from these carriers to tumor cells are significant challenges in cancer therapy. In this study, we developed a novel drug delivery carrier derived from mesoporous silica, dually modified with the tumor-homing cyclic peptide iRGD (CRGDKGPDC) and the pH-responsive polymer poly(2-ethyl-2-oxazoline) (PEOz) for treating triple-negative
-
Investigating distributions of inhaled aerosols in the lungs of post-COVID-19 clusters through a unified imaging and modeling approach Eur. J. Pharm. Sci. (IF 4.6) Pub Date : 2024-02-08 Xuan Zhang, Frank Li, Prathish K. Rajaraman, Alejandro P. Comellas, Eric A. Hoffman, Ching-Long Lin
Recent studies, based on clinical data, have identified sex and age as significant factors associated with an increased risk of long COVID. These two factors align with the two post-COVID-19 clusters identified by a deep learning algorithm in computed tomography (CT) lung scans: Cluster 1 (C1), comprising predominantly females with small airway diseases, and Cluster 2 (C2), characterized by older individuals
-
Safety, tolerability, pharmacokinetics and neutrophil elastase inhibitory effects of Sivelestat: A randomized, double-blind, placebo-controlled single- and multiple-dose escalation study in Chinese healthy subjects Eur. J. Pharm. Sci. (IF 4.6) Pub Date : 2024-02-07 Kun Li, Lingfang Dong, Shan Gao, Jingying Zhang, Yinghua Feng, Li Gu, Jie Yang, Xing Liu, Yaqin Wang, Zhenkun Mao, Dandan Jiang, Zhengchao Xia, Guoliang Zhang, Jingwen Tang, Peizhi Ma, Wei Zhang
[Display omitted] A randomized, double-blind, placebo-controlled single- and multiple-dose escalation clinical study was performed to explore alternative dosing regimen of Sivelestat.
-
Water-mediated phase transformations of posaconazole: An intricate jungle of crystal forms Eur. J. Pharm. Sci. (IF 4.6) Pub Date : 2024-02-07 Matteo Guidetti, Rolf Hilfiker, Martin Kuentz, Annette Bauer-Brandl, Fritz Blatter
Posaconazole is a broad-spectrum antifungal agent exhibiting rich polymorphism. Up to now, a total of fourteen different crystal forms have been reported, sometimes with an ambiguous nomenclature, but less is known about their properties and stability relationships. Investigating the solid-state of a drug compound is essential to identify the most stable form under working conditions and to prevent
-
Effects of H2S-donor ascorbic acid derivative and ischemia/reperfusion-induced injury in isolated rat hearts Eur. J. Pharm. Sci. (IF 4.6) Pub Date : 2024-02-06 Bence Tánczos, Virág Vass, Erzsébet Szabó, Miklós Lovas, Rasha Ghanem Kattoub, Ilona Bereczki, Anikó Borbás, Pál Herczegh, Árpád Tósaki
Hydrogen sulfide (HS), a gasotransmitter, plays a crucial role in vasorelaxation, anti-inflammatory processes and mitigating myocardial ischemia/reperfusion-induced injury by regulating various signaling processes. We designed a water soluble HS-releasing ascorbic acid derivative, BM-164, to combine the beneficial cardiovascular and anti-inflammatory effects of HS with the excellent water solubility
-
-
The role of partial area under the curve and maximum concentrations in assessing the bioequivalence of long-acting injectable formulation of exenatide_A sensitivity analysis Eur. J. Pharm. Sci. (IF 4.6) Pub Date : 2024-02-03 Hong-Jaan Wang, Li-Feng Hsu
-
Predicting the intrinsic membrane permeability of Caco-2/MDCK cells by the solubility-diffusion model Eur. J. Pharm. Sci. (IF 4.6) Pub Date : 2024-02-02 Carolin Dahley, Tim Böckmann, Andrea Ebert, Kai-Uwe Goss
-
Small molecules modified mesoporous silica nanoparticles orally deliver indomethacin with synergistic effect Eur. J. Pharm. Sci. (IF 4.6) Pub Date : 2024-02-02 Shiliang Yin, Lin Cai, Xuan Li, Kai Lin, Xianbao Shi, Hong Zhang, Lijie Wang, Jing Li
-
A remodeled ivermectin polycaprolactone-based nanoparticles for inhalation as a promising treatment of pulmonary inflammatory diseases Eur. J. Pharm. Sci. (IF 4.6) Pub Date : 2024-01-30 Sabaa Wafiq Mohammed, Nagia Ahmed El-Megrab, Azza A. Hasan, Eman Gomaa
-
Evaluation of omadacycline dosing regimens in Chinese using population pharmacokinetic-pharmacodynamic analysis Eur. J. Pharm. Sci. (IF 4.6) Pub Date : 2024-02-01 Kun Wang, Yusong Zhu, Fengyan Xu, Lucy Liu, Lichuan Liu, Mengling Shi, Jing Nie, Harald Reinhart, Jing Liu, Yuying Gao, Xia Pu
-
Management of oxidative stress for cell therapy through combinational approaches of stem cells, antioxidants, and photobiomodulation Eur. J. Pharm. Sci. (IF 4.6) Pub Date : 2024-02-01 Rezvan Asgari, Yasaman Zandi Mehran, Hans Michael Weber, Micheal Weber, Sayed Ali Golestanha, Seyed Mohammad Hosseini Kazerouni, Farzad Panahi, Pantea Mohammadi, Kamran Mansouri
-
Silk fibroin-based dressings with antibacterial and anti-inflammatory properties Eur. J. Pharm. Sci. (IF 4.6) Pub Date : 2024-01-26 David González-Restrepo, Augusto Zuluaga-Vélez, Lina M. Orozco, Juan C. Sepúlveda-Arias
-
Application of nanofiber-based drug delivery systems in improving anxiolytic effect of new 1,2,3-triazolo-1,4-benzodiazepine derivatives Eur. J. Pharm. Sci. (IF 4.6) Pub Date : 2024-01-28 Iryna Botsula, Johannes Sсhavikin, Jyrki Heinämäki, Ivo Laidmäe, Maryna Mazur, Ain Raal, Oleh Koshovyi, Igor Kireyev, Valentyn Chebanov
-
Methotrexate-loaded hyaluronan-modified liposomes integrated into dissolving microneedles for the treatment of psoriasis Eur. J. Pharm. Sci. (IF 4.6) Pub Date : 2024-01-28 Shulin Shen, Xi Zheng, Xu Dong, Min Fang, Aiqun Wan, Tong Zhu, Qingliang Yang, Jing Xie, Qinying Yan
-
Modifying peptide/lipid-associated nucleic acids (PLANAs) for CRISPR/Cas9 ribonucleoprotein delivery Eur. J. Pharm. Sci. (IF 4.6) Pub Date : 2024-01-21 Abdulelah Alhazza, Parvin Mahdipoor, Ryley Hall, Arthur Manda, Sandeep Lohan, Keykavous Parang, Hamidreza Montazeri Aliabadi
-
Physiologically based pharmacokinetic modeling to predict maternal pharmacokinetics and fetal carbamazepine exposure during pregnancy Eur. J. Pharm. Sci. (IF 4.6) Pub Date : 2024-01-18 Yuying Chen, Meng Ke, Weipeng Fang, Yaojie Jiang, Rongfang Lin, Wanhong Wu, Pinfang Huang, Cuihong Lin
-
Pitfalls in evaluating permeability experiments with Caco-2/MDCK cell monolayers Eur. J. Pharm. Sci. (IF 4.6) Pub Date : 2024-01-16 Andrea Ebert, Carolin Dahley, Kai-Uwe Goss
-
ProtT5 and random forests-based viscosity prediction method for therapeutic mAbs Eur. J. Pharm. Sci. (IF 4.6) Pub Date : 2024-01-19 Xiaohu Hao, Long Fan
-
Trifluoromethyl quinoline derivative targets inhibiting HDAC1 for promoting the acetylation of histone in cervical cancer cells Eur. J. Pharm. Sci. (IF 4.6) Pub Date : 2024-01-19 Ting Zhang, Changhua Zhou, Mengfan Lv, Jia Yu, Sha Cheng, Xudong Cui, Xinwei Wan, Mashaal Ahmad, Bixue Xu, Juan Qin, Xueling Meng, Heng Luo
-
Advancements in preclinical human-relevant modeling of pulmonary vasculature on-chip Eur. J. Pharm. Sci. (IF 4.6) Pub Date : 2024-01-19 Quoc Vo, Kambez H. Benam
-
Erratum to “Sodium glycodeoxycholate and sodium deoxycholate as epithelial permeation enhancers: in vitro and ex vivo intestinal and buccal bioassays” [European Journal of Pharmaceutical Sciences 159 (2021) 105737] Eur. J. Pharm. Sci. (IF 4.6) Pub Date : 2024-01-18 David J. Brayden, Vivien Stuettgen
Abstract not available
-
-
Microparticles and multi-unit systems for advanced drug delivery Eur. J. Pharm. Sci. (IF 4.6) Pub Date : 2024-01-14 Nikolett Kállai-Szabó, Dóra Farkas, Miléna Lengyel, Bálint Basa, Christian Fleck, István Antal
-
Using molecularly dissolved drug concentrations in PBBMs improves the prediction of oral absorption from supersaturating formulations Eur. J. Pharm. Sci. (IF 4.6) Pub Date : 2024-01-14 Florentin Lukas Holzem, Jeannine Petrig Schaffland, Martin Brandl, Annette Bauer-Brandl, Cordula Stillhart
-
Development of a canine artificial colonic mucus model for drug diffusion studies Eur. J. Pharm. Sci. (IF 4.6) Pub Date : 2024-01-12 V. Barmpatsalou, M. Tjakra, L. Li, I.R. Dubbelboer, E. Karlsson, B. Pedersen Lomstein, C.A.S. Bergström
-
J24335 exerts neuroprotective effects against 6-hydroxydopamine-induced lesions in PC12 cells and mice Eur. J. Pharm. Sci. (IF 4.6) Pub Date : 2024-01-09 Zhijian Pan, Min Shao, Chen Zhao, Xuanjun Yang, Haitao Li, Guozhen Cui, Xiaonan Liang, Chao-Wu Yu, Qingqing Ye, Cheng Gao, Lijun Di, Ji-Wang Chern, Hefeng Zhou, Simon Ming-Yuen Lee
-
Physiologically based pharmacokinetic modeling of ritonavir-oxycodone drug interactions and its implication for dosing strategy Eur. J. Pharm. Sci. (IF 4.6) Pub Date : 2024-01-08 Liang Zheng, Wei Zhang, Klaus T. Olkkola, André Dallmann, Liang Ni, Yingjie Zhao, Ling Wang, Qian Zhang, Wei Hu
-
Communication between nonalcoholic fatty liver disease and atherosclerosis: Focusing on exosomes Eur. J. Pharm. Sci. (IF 4.6) Pub Date : 2024-01-03 Xiaona Zhao, Xinxin Kong, Zhoujun Cui, Zejin Zhang, Minghui Wang, Guoqing Liu, Honggang Gao, Jing Zhang, Wei Qin
-
IGF-PLGA microspheres promote angiogenesis and accelerate skin flap repair and healing by inhibiting oxidative stress and regulating the Ang 1/Tie 2 signaling pathway Eur. J. Pharm. Sci. (IF 4.6) Pub Date : 2024-01-02 Fei Hu, Kai Huang, Hanbo Zhang, Wenjie Hu, Songlin Tong, Hongming Xu
-
Pharmacokinetics, biodistribution, and in vivo toxicity of 7-nitroindazole loaded in pegylated and non-pegylated nanoemulsions in rats Eur. J. Pharm. Sci. (IF 4.6) Pub Date : 2024-01-07 Angela Patricia França, Thais Alves Silva, Daniela Schulz, Leonardo Gomes-Pereira, Livia Melo Arruda Cunha, Merita Pereira Gonçalves, João Victor Soares Vieira, Mariele Paludetto Sanches, Natalia Koehler, Sharbel Maluf, Anicleto Poli, José Eduardo da Silva-Santos, Jamil Assreuy, Elenara Lemos-Senna
-
Evaluation of in vitro dissolution profiles of modified-release metoprolol succinate tablets crushed using mortar and pestle technique Eur. J. Pharm. Sci. (IF 4.6) Pub Date : 2024-01-07 Fatma Kir, Fatima K. Al-Sulaiti, Selma Sahin
-
Development strategy of novel drug formulations for the delivery of doxycycline in the treatment of wounds of various etiologies Eur. J. Pharm. Sci. (IF 4.6) Pub Date : 2024-01-06 Olena Saliy, Mariia Popova, Hanna Tarasenko, Olga Getalo
-
Enhancement of the solubility and oral bioavailability of altrenogest through complexation with hydroxypropyl-β-cyclodextrin Eur. J. Pharm. Sci. (IF 4.6) Pub Date : 2024-01-04 Wojun Chen, Xianwen Zheng, Wenxuan Lao, Hongxin Wang, Shengfeng Chen, Canying Liu, Zhisheng Chen, Yinshan Bai, Hui Zhang, Xiaoshu Zhan, Bingyun Wang
-
Antiplatelet activity and toxicity profile of novel phosphonium salts derived from Michael reaction Eur. J. Pharm. Sci. (IF 4.6) Pub Date : 2024-01-04 Asma Haffouz, Haitham Elleuch, Bassem Khemakhem, Ikram Ben Amor, Amira Jerbi, Jalel Gargouri, Emna Sahli, Noureddine Mhadhbi, Houcine Ghalla, Farhat Rezgui, Ali Gargouri, Basma HadjKacem
-
Aerosol delivery and spatiotemporal tissue distribution of hydroxychloroquine in rat lung Eur. J. Pharm. Sci. (IF 4.6) Pub Date : 2024-01-04 Wenhao Xia, Aditya R Kolli, Arkadiusz K Kuczaj, Justyna Szostak, Sharon Lam, Wei Wen Toh, Asef Purwanti, Wei Teck Tan, Raymond Ng, Blaine Phillips, Manuel C Peitsch, Julia Hoeng
-
Recent advances and clinical translation of liposomal delivery systems in cancer therapy Eur. J. Pharm. Sci. (IF 4.6) Pub Date : 2024-01-01 Jiayi Chen, Siyuan Hu, Man Sun, Jianan Shi, Huan Zhang, Hongmei Yu, Zhaogang Yang
-
Exploring the impact of CYP2D6 and UGT2B7 gene-drug interactions, and CYP-mediated DDI on oxycodone and oxymorphone pharmacokinetics using physiologically-based pharmacokinetic modeling and simulation Eur. J. Pharm. Sci. (IF 4.6) Pub Date : 2024-01-01 Marian Klose, Rodrigo Cristofoletti, Carolina de Miranda Silva, Naveen Mangal, Jacques Turgeon, Veronique Michaud, Lawrence J Lesko, Stephan Schmidt
-
Construction of chrysophanol loaded nanoparticles with N-octyl-O-sulfate chitosan for enhanced nephroprotective effect Eur. J. Pharm. Sci. (IF 4.6) Pub Date : 2023-12-27 Qingxue Wei, Fuping Gao, Leiping Gao, Hong Gao, Jian Zhang, Rui Bao, Hang Zhang, Jiapeng Wang, Qiusheng Shen, Mingjia Gu
-
Cancer sensitizing effect of deazaflavin analogs is associated with increased intracellular drug accumulation Eur. J. Pharm. Sci. (IF 4.6) Pub Date : 2023-12-29 Zakia Belhadj, Samuel Offei, Blake A. Jacobson, Daniel Cambron, Robert A. Kratzke, Zhengqiang Wang, Jiashu Xie
-
A comparison of USP 2 and µDISS Profiler™ apparatus for studying dissolution phenomena of ibuprofen and its salts Eur. J. Pharm. Sci. (IF 4.6) Pub Date : 2023-12-26 Laurin Zöller, Alex Avdeef, Eva Karlsson, Anders Borde, Sara Carlert, Christoph Saal, Jennifer Dressman
-
The effect of mixing on the dispersibility of adhesive mixtures for inhalation. Comparison of high shear and Turbula mixers Eur. J. Pharm. Sci. (IF 4.6) Pub Date : 2023-12-20 Kyrre Thalberg, Love Ivarsson, Mårten Svensson, Peter Elfman, Ann Ohlsson, Jackie Stuckel, Ann-Marie Lyberg
-
Harmonizing the craft of crafting clinically endorsed small-molecule BCR-ABL tyrosine kinase inhibitors for the treatment of hematological malignancies Eur. J. Pharm. Sci. (IF 4.6) Pub Date : 2023-12-17 Lu Sun, Peng-Cheng Yang, Li Luan, Jin-Feng Sun, Ya-Tao Wang